Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2022-08-16 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团独立董事关于提名公司第十届董事会候选人的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on the nomination of candidates for the company's 10th board of directors. It references compliance with listing rules and company bylaws, and it is a formal statement regarding board candidate qualifications and nomination procedures. This type of document is related to board or management information, specifically announcements about changes or nominations in the company's board of directors. It is not a full report, financial statement, or regulatory filing, but a management/board information announcement.
2022-08-16 Chinese
健民集团关于独立董事提名人及候选人声明的公告
Board/Management Information Classification · 95% confidence The document is a detailed statement nominating and declaring the qualifications and independence of candidates for independent director positions at a listed company, including compliance with relevant laws and regulations. It contains no financial data, earnings, or management discussion, nor is it an announcement of a report or voting results. It is related to board/management information, specifically about board nominations and qualifications of directors. Therefore, it fits best under the category of Board/Management Information (MANG). The document length and content confirm it is not a brief announcement or a regulatory filing. Confidence is high due to the clear focus on director nomination and qualifications.
2022-08-16 Chinese
健民药业集团股份有限公司收购股权涉及的浙江华方医护有限公司股东全部权益价值评估说明
Audit Report / Information Classification · 95% confidence The document is a detailed asset valuation report prepared by Wan Bang Asset Appraisal Co., Ltd. for Jianmin Pharmaceutical Group Co., Ltd. regarding the acquisition of equity in Zhejiang Huafang Medical Care Co., Ltd. It includes extensive financial data, asset and liability valuations, evaluation methods, and detailed explanations of asset categories such as current assets, fixed assets, long-term investments, and usage rights. The document is comprehensive, contains actual financial data, and is focused on asset valuation related to an acquisition transaction. It is not a general annual or quarterly report, nor is it a simple announcement or certification. The content aligns with an Audit Report / Information (AR) category, as it is a standalone asset appraisal report with detailed financial and valuation information related to a specific transaction.
2022-08-16 Chinese
健民集团独立董事关于受让股权暨关联交易的事前意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding a proposed equity transfer and related party transaction to be submitted to the board for approval. It references compliance with stock exchange listing rules and company bylaws, and provides an assessment of fairness and reasonableness of the transaction price. The content is focused on governance and board-level decision-making rather than financial results, audit, or shareholder voting outcomes. It is not a full report, earnings release, or regulatory filing but rather a management/board-related opinion on a transaction. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report.
2022-08-16 Chinese
健民集团关于签订《合资合作意向书》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a joint venture cooperation intention letter between the company and another party. It outlines the basic information of the cooperation, the parties involved, the intended structure of the joint venture, and the risks associated with the cooperation. The document explicitly states that the intention letter is a non-binding framework agreement and that formal contracts and approvals are yet to be completed. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is relatively short (3993 characters) and serves as a formal announcement of a cooperation intention rather than a full report or detailed financial disclosure. Therefore, it fits best into the category of a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-03 Chinese
健民集团关于召开2022年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2022 semi-annual performance explanation meeting (业绩说明会) for investors. It includes the meeting time, location, participation method, and contact information. It references the 2022 half-year report but does not contain the report itself or substantive financial data. The document is short (1605 characters) and serves to inform investors about the upcoming event rather than presenting financial results or analysis. Therefore, it is an Investor Presentation announcement or a notice about an investor meeting rather than the report itself. Given the definitions, this fits best under Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position through an interactive meeting.
2022-07-22 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.